Pdt Partners, LLC Amicus Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1.58 Billion
Q2 2025

A detailed history of Pdt Partners, LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 506,052 shares of FOLD stock, worth $4.15 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

506,052

Previous 741,315 31.74%

Holding current value

$4.15 Million

Previous $6.05 Million 52.07%

% of portfolio

0.18%

Previous 0.47%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$5.64 - $8.0 $1.33 Million - $1.88 Million	-235,263 Reduced 31.74%	506,052 $2.9 Million
Q1 2025 May 15, 2025	BUY	$8.16 - $9.85 $3.17 Million - $3.83 Million	388,817 Added 110.3%	741,315 $6.05 Million
Q4 2024 Feb 14, 2025	BUY	$9.36 - $12.01 $931,685 - $1.2 Million	99,539 Added 39.35%	352,498 $3.32 Million
Q3 2024 Nov 14, 2024	BUY	$9.55 - $12.09 $2.42 Million - $3.06 Million	252,959 New	252,959 $2.7 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $299,559 - $388,938	30,505 New	30,505 $318,000
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $205,097 - $366,081	-32,921 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.89 - $12.48 $259,746 - $410,854	32,921 New	32,921 $312,000
Q3 2019 Nov 14, 2019	SELL	$8.02 - $13.25 $2.54 Million - $4.19 Million	-316,400 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $220,879 - $306,240	-22,000 Reduced 6.5%	316,400 $4.3 Million
Q4 2018 Feb 14, 2019	BUY	$8.38 - $13.44 $2.06 Million - $3.3 Million	245,816 Added 265.51%	338,400 $3.24 Million
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $1.07 Million - $1.53 Million	92,584 New	92,584 $1.12 Million

Others Institutions Holding FOLD

# of Institutions

302

Shares Held

332M

Call Options Held

396K

Put Options Held

249K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.3B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account